Belgium· BE-AMP-SAM662789-00
Qalsody 100 mg
A tofersen product containing tofersen, registered in Belgium by Biogen Netherlands. The same ATC class is registered in 11 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Tofersen is registered in 11 of 19 countries.
Countries holding a registration under ATC N07XX22 (tofersen), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 7 of them publish a price we can compare per daily dose
Tofersen · ATC N07XX22
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Tofersen
- Manufacturer
- Biogen Netherlands
- Country
- Belgium (BE)
- ATC code
- N07XX22
- ATC class
- Tofersen
- Defined daily dose
- 3.57 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb5819586
- be_apb7748635
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tofersen in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaQALSODYBiogen Netherlands B.V., Badhoevedorp
- SpainQALSODY 100 MG SOLUCIÓN INYECTABLEBiogen Netherlands B.V.
- FinlandQalsodyBiogen Netherlands B.V.
- IrelandQalsody 100 mg solution for injectionBiogen Netherlands B.V.
- IcelandQalsodyBiogen Netherlands B.V.
- NetherlandsQalsody 100 mg oplossing voor injectieBiogen Netherlands B.V.
- PolandQalsody 100 mg roztwór do wstrzykiwańBiogen Netherlands B.V.
- SwedenQalsody 100 mg Injektionsvätska, lösningBiogen Netherlands B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Qalsody
- Liechtenstein · Qalsody
- Norway · Qalsody
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/80a8b1f8-e5f7-4df7-b488-5cedda9fe987 GET /v1/drugs/80a8b1f8-e5f7-4df7-b488-5cedda9fe987?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Qalsody 100 mg",
"name_fr": "Qalsody 100 mg",
"name_nl": "Qalsody 100 mg",
"amp_code": "SAM662789-00",
"strengths": [
"6.7000",
"6.7000",
"52.0000"
],
"pack_count": 1,
"substances": [
"Tofersen",
"Potassium Chloride",
"Sodium"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Tofersen",
"authorisation_numbers": [
"EU/1/23/1783/001"
]
}See everything about tofersen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.